The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Immunodiagnostic Systems Plc

4 Jun 2021 09:23

RNS Number : 8764A
Peel Hunt LLP
04 June 2021
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Immunodiagnostic Systems Holdings Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Immunodiagnostic Systems Holdings Plc

(d) Date dealing undertaken:

03 June 2021

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Sell

15,000

375.00 GBx

375.00 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

04 June 2021

 

Contact name:

Kathleen Lloyd

Telephone number:

0207 418 8911

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERUSUWRAOUNRRR
Date   Source Headline
28th Jun 201612:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20161:42 pmRNSDirector/PDMR Shareholding
22nd Jun 20167:45 amRNSAnnual Report and Accounts
22nd Jun 20167:00 amRNSPreliminary Results
9th Jun 20167:00 amRNSUpdate re Royalty Revenues
20th May 20169:20 amRNSHolding(s) in Company
6th May 201610:30 amRNSLaunch of IDS-iSYS 17-OH Progesterone assay
25th Apr 20167:00 amRNSFull Year Trading Update
8th Jan 20167:00 amRNSRelocation of Automated related Assay Activity
4th Jan 20167:30 amRNSPaul Martin joins as Group Finance Director
18th Dec 20159:43 amRNSLaunch of Salivary Cortisol Hypertension Assay
30th Nov 201510:41 amRNSHolding(s) in Company
24th Nov 20157:00 amRNSHalf Yearly Report
22nd Oct 20152:22 pmRNSDirectorate Change
21st Oct 20155:00 pmRNSHolding(s) in Company - Replacement
20th Oct 20152:23 pmRNSDirectorate Change
13th Oct 20157:00 amRNSTrading Statement
8th Oct 20154:40 pmRNSHolding(s) in Company
1st Oct 201512:05 pmRNSTotal Voting Rights
30th Sep 20152:05 pmRNSHolding(s) in Company
15th Sep 20154:32 pmRNSAdditional Listing
4th Aug 20152:43 pmRNSResult of AGM
4th Aug 20157:00 amRNSAGM Statement
29th Jun 20153:18 pmRNSRe Report and Accounts and AGM - Replacement
29th Jun 201511:59 amRNSRe Report and Accounts and AGM
29th Jun 20157:15 amRNSDirectorate Change
23rd Jun 20157:00 amRNSFinal Results
12th Jun 20154:00 pmRNSBoard Appointment
10th Jun 20157:00 amRNSDirectorate Change
29th May 20157:00 amRNSTrading Statement
21st Apr 20157:00 amRNSTrading Statement
2nd Apr 20157:43 amRNSPatricio Lacalle Joins as Chief Executive Officer
9th Feb 201510:30 amRNSHolding(s) in Company
3rd Feb 20157:00 amRNSDirectorate Change
6th Jan 20155:04 pmRNSAdditional Listing
5th Jan 20155:10 pmRNSAdditional Listing
24th Dec 20141:30 pmRNSDirectorate Change
19th Dec 201410:47 amRNSHolding(s) in Company
19th Dec 20148:40 amRNSHolding(s) in Company
18th Dec 20149:30 amRNSDirector/PDMR Shareholding
15th Dec 20145:13 pmRNSHolding(s) in Company
12th Dec 20147:00 amRNSLaunch of 1,25-Dihydroxy Vitamin D Assay
8th Dec 20143:38 pmRNSHolding(s) in Company
4th Dec 20145:36 pmRNSDirectorate Change
4th Dec 20144:27 pmRNSDirector/PDMR Shareholding
25th Nov 20147:00 amRNSDirectorate Change
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20145:20 pmRNSPatrik Dahlen Resigns as CEO
14th Oct 20147:00 amRNSTrading Update
15th Sep 20147:00 amRNSUpdate on current trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.